Antidepressants induce cellular insulin resistance by activation of IRS-1 kinases

Molecular and Cellular Neuroscience

Volumn 36, Issue 3, 2007, Pages 305-312

  Levkovitz, Yechiel ^a   Ben shushan, Galit ^b   Hershkovitz, Avia ^b   Isaac, Roi ^a   Gil Ad, Irit ^a   Shvartsman, Dima ^a   Ronen, Denise ^b   Weizman, Abraham ^a   Zick, Yehiel ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Antidepressants; Insulin receptor substrates; Insulin resistance; Selective serotonin reuptake inhibitors

Indexed keywords

INSULIN RECEPTOR SUBSTRATE 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OLANZAPINE; PAROXETINE; PROTEIN KINASE B; S6 KINASE; SERTRALINE; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; INSULIN RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT;

ANIMALS; CELL LINE, TUMOR; DIABETES MELLITUS; ENZYME ACTIVATION; INSULIN; INSULIN RESISTANCE; JNK MITOGEN-ACTIVATED PROTEIN KINASES; METABOLIC SYNDROME X; PAROXETINE; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RATS; SERINE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SIGNAL TRANSDUCTION;

RATTUS;

EID: 35448938465     PISSN: 10447431     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcn.2007.05.009     Document Type: Article

References (62)

1. Aguirre V., Uchida T., Yenush L., Davis R., and White M.F. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J. Biol. Chem. 275 (2000) 9047-9054
2. Aguirre V., Werner E.D., Giraud J., Lee Y.H., Shoelson S.E., and White M.F. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J. Biol. Chem. 277 (2002) 1531-1537
3. Altamura A.C., Moro A.R., and Percudani M. Clinical pharmacokinetics of fluoxetine. Clin. Pharmacokinet. 26 (1994) 201-214
4. Arve A.T., and Preskorn S.H. Interactions of serotonin reuptake inhibitors with tricyclic antidepressants. Arch. Gen. Psychiatry 52 (1995) 783-784
5. Barbey J.T., and Roose S.P. SSRI safety in overdose. J. Clin. Psychiatry 59 suppl 15 (1998) 42-48
6. Bolo N.R., Hode Y., Nedelec J.F., Laine E., Wagner G., and Macher J.P. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 23 (2000) 428-438
7. Chou C.T., He S., and Jan C.R. Paroxetine-induced apoptosis in human osteosarcoma cells: activation of p38 MAP kinase and caspase-3 pathways without involvement of [Ca(2+)](i) elevation. Toxicol. Appl. Pharmacol. (2006)
8. De Fea K., and Roth R.A. Protein kinase C modulation of insulin receptor substrate-1 tyrosine phosphorylation requires serine 612. Biochemistry 36 (1997) 12939-12947
9. Delahaye L., Mothe S.I., Myers M.G., White M.F., and Van O.E. Interaction of insulin receptor substrate-1 (IRS-1) with phosphatidylinositol 3-kinase: effect of substitution of serine for alanine in potential IRS-1 serine phosphorylation sites. Endocrinology 139 (1998) 4911-4919
10. Despres J.P., and Lemieux I. Abdominal obesity and metabolic syndrome. Nature 444 (2006) 881-887
11. Eck M.J., Dhe P.S., Trub T., Nolte R.T., and Shoelson S.E. Structure of the IRS-1 PTB domain bound to the juxtamembrane region of the insulin receptor. Cell 85 (1996) 695-705
12. Engl J., Laimer M., Niederwanger A., Kranebitter M., Starzinger M., Pedrini M.T., Fleischhacker W.W., Patsch J.R., and Ebenbichler C.F. Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. Mol. Psychiatry 10 (2005) 1089-1096
13. Fava M., Judge R., Hoog S.L., Nilsson M.E., and Koke S.C. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J. Clin. Psychiatry 61 (2000) 863-867
14. Finkel M.S., Laghrissi-Thode F., Pollock B.G., and Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol. Bull. 32 (1996) 653-658
15. Fryer J.D., and Lukas R.J. Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function. J. Neurochem. 72 (1999) 1117-1124
16. Ganguli R. Weight gain associated with antipsychotic drugs. J. Clin. Psychiatry 60 Suppl 21 (1999) 20-24
17. Garcia-Colunga J., Awad J.N., and Miledi R. Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac). Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 2041-2044
18. Gram L. Fluoxetine. N. Engl. J. Med. 331 (1994) 1354-1361
19. Hemi R., Paz K., Wertheim N., Karasik A., Zick Y., and Kanety H. Transactivation of ErbB2 and ErbB3 by tumor necrosis factor-alpha and anisomycin leads to impaired insulin signaling through serine/threonine phosphorylation of IRS proteins. J. Biol. Chem. 277 (2002) 8961-8969
20. Herschkovitz, A., Liu, Y.-F., Ilan, E., Ronen, D., Boura-Halfon, S., Zick, Y., 2007. Common inhibitory serine sites phosphorylated by IRS-1 kinases, triggered by insulin and inducers of insulin resistance. Manuscript Submitted.
21. Himmerich H., Schuld A., Haack M., Kaufmann C., and Pollmacher T. Early prediction of changes in weight during six weeks of treatment with antidepressants. J. Psychiatr. Res. 38 (2004) 485-489
22. Hinze-Selch D., Schuld A., Kraus T., Kuhn M., Uhr M., Haack M., and Pollmacher T. Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: a longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology 23 (2000) 13-19
23. Hirosumi J., Tuncman G., Chang L., Gorgun C.Z., Uysal K.T., Maeda K., Karin M., and Hotamisligil G.S. A central role for JNK in obesity and insulin resistance. Nature 420 (2002) 333-336
24. Holsboer F., and Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr. Rev. 17 (1996) 187-205
25. Jakobsen S.N., Hardie D.G., Morrice N., and Tornqvist H.E. 5′-AMP-activated protein kinase phosphorylates IRS-1 on Ser-789 in mouse C2C12 myotubes in response to 5-aminoimidazole-4-carboxamide riboside. J. Biol. Chem. 276 (2001) 46912-46916
26. Kahn B.B., and Flier J.S. Obesity and insulin resistance. J. Clin. Invest. 106 (2000) 473-481
27. Karson C.N., Newton J.E., Livingston R., Jolly J.B., Cooper T.B., Sprigg J., and Komoroski R.A. Human brain fluoxetine concentrations. J. Neuropsychiatry Clin. Neurosci. 5 (1993) 322-329
28. Khan A.H., and Pessin J.E. Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways. Diabetologia 45 (2002) 1475-1483
29. Kim J.A., Yeh D.C., Ver M., Li Y., Carranza A., Conrads T.P., Veenstra T.D., Harrington M.A., and Quon M.J. Phosphorylation of Ser24 in the pleckstrin homology domain of insulin receptor substrate-1 by Mouse Pelle-like kinase/interleukin-1 receptor-associated kinase: cross-talk between inflammatory signaling and insulin signaling that may contribute to insulin resistance. J. Biol. Chem. 280 (2005) 23173-23183
30. + channels by the antidepressant paroxetine. J. Pharmacol. Sci. 102 (2006) 278-287
31. Lawlor M.A., and Alessi D.R. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?. J. Cell Sci. 114 (2001) 2903-2910
32. LeRoith D., and Zick Y. Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care 24 (2001) 588-597
33. Levkovitz Y., Gil-Ad I., Zeldich E., Dayag M., and Weizman A. Differential induction of apoptosis by antidepressants in glioma and neuroblastoma cell lines: evidence for p-c-Jun, cytochrome c, and caspase-3 involvement. J. Mol. Neurosci. 27 (2005) 29-42
34. Liu Y.F., Herschkovitz A., Boura H.S., Ronen D., Paz K., Leroith D., and Zick Y. Serine phosphorylation proximal to its phosphotyrosine binding domain inhibits insulin receptor substrate 1 function and promotes insulin resistance. Mol. Cell. Biol. 24 (2004) 9668-9681
35. Liu Y.F., Paz K., Herschkovitz A., Alt A., Tennenbaum T., Sampson S.R., Ohba M., Kuroki T., LeRoith D., and Zick Y. Insulin stimulates PKCzeta-mediated phosphorylation of insulin receptor substrate-1 (IRS-1). A self-attenuated mechanism to negatively regulate the function of IRS proteins. J. Biol. Chem. 276 (2001) 14459-14465
36. Lundmark J., Thomsen I.S., Fjord-Larsen T., Manniche P.M., Mengel H., Moller-Nielsen E.M., Pauser H., and Walinder J. Paroxetine: pharmacokinetic and antidepressant effects in the elderly. Acta Psychiatr. Scand. 80 Suppl. 350 (1989) 76-80
37. Maertens C., Droogmans G., Verbesselt R., and Nilius B. Block of volume-regulated anion channels by selective serotonin reuptake inhibitors. Naunyn-Schmiedeberg's Arch. Pharmacol. 366 (2002) 158-165
38. Moeschel K., Beck A., Weigert C., Lammers R., Kalbacher H., Voelter W., Schleicher E.D., Haring H.U., and Lehmann R. Protein kinase C-zeta-induced phosphorylation of Ser318 in receptor substrate-1 (IRS-1) attenuates the interaction with the receptor and the tyrosine phosphorylation of IRS-1. J. Biol. Chem. 279 (2004) 25157-25163
39. Mothe I., and Van Obberghen E. Phosphorylation of insulin receptor substrate-1 on multiple serine residues, 612, 632, 662, and 731, modulates insulin action. J. Biol. Chem. 271 (1996) 11222-11227
40. Newcomer J.W. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J. Clin. Psychiatry 68 Suppl 1 (2007) 20-27
41. Ozes O.N., Akca H., Mayo L.D., Gustin J.A., Maehama T., Dixon J.E., and Donner D.B. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 4640-4645
42. + channels by antidepressant drugs. J. Pharmacol. Exp. Ther. 284 (1998) 208-214
43. Pariante C.M., Makoff A., Lovestone S., Feroli S., Heyden A., Miller A.H., and Kerwin R.W. Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters. Br. J. Pharmacol. 134 (2001) 1335-1343
44. Paterson G.J., Ohashi Y., Reynolds G.P., Pratt J.A., and Morris B.J. Selective increases in the cytokine, TNFalpha, in the prefrontal cortex of PCP-treated rats and human schizophrenic subjects: influence of antipsychotic drugs. J. Psychopharmacol. 20 (2006) 636-642
45. Paz K., Hemi R., LeRoith R., Karasik A., Elhanany E., Kanety H., and Zick Y. A molecular basis for insulin resistance: elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J. Biol. Chem. 272 (1997) 29911-29918
46. Pederson T.M., Kramer D.L., and Rondinone C.M. Serine/threonine phosphorylation of IRS-1 triggers its degradation: possible regulation by tyrosine phosphorylation. Diabetes 50 (2001) 24-31
47. Pijl H., and Meinders A.E. Bodyweight change as an adverse effect of drug treatment. Mechanisms and management. Drug Safety 14 (1996) 329-342
48. Preksorn S.H. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin. Pharmacokinet. 32 Suppl 1 (1997) 1-21
49. Raeder M.B., Bjelland I., Emil-Vollset S., and Steen V.M. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study. J. Clin. Psychiatry 67 (2006) 1974-1982
50. Reaven G. Insulin resistance, type 2 diabetes mellitus, and cardiovascular disease: the end of the beginning. Circulation 112 (2005) 3030-3032
51. Saltiel A.R., and Pessin J.E. Insulin signaling pathways in time and space. Trends Cell Biol. 12 (2002) 65-71
52. Stanton T., Bolden-Watson C., Cusack B., and Richelson E. Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics. Biochem. Pharmacol. 45 (1993) 2352-2354
53. Sun X.J., Rothenberg P., Kahn C.R., Backer J.M., Araki E., Wilden P.A., Cahill D.A., Goldstein B.J., and White M.F. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 352 (1991) 73-77
54. Tirosh A., Potashnik R., Bashan N., and Rudich A. Oxidative stress disrupts insulin-induced cellular redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. A putative cellular mechanism for impaired protein kinase B activation and GLUT4 translocation. J. Biol. Chem. 274 (1999) 10595-10602
55. Tytgat J., Maertens C., and Daenens P. Effect of fluoxetine on a neuronal, voltage-dependent potassium channel (Kv1.1). Br. J. Pharmacol. 122 (1997) 1417-1424
56. Vincent A.M., and Feldman E.L. Control of cell survival by IGF signaling pathways. Growth Horm. IGF Res. 12 (2002) 193-197
57. Voliovitch H., Schindler D.G., Hadari Y.R., Taylor S.I., Accili D., and Zick Y. Tyrosine phosphorylation of insulin receptor substrate-1 in vivo depends upon the presence of its pleckstrin homology region. J. Biol. Chem. 270 (1995) 18083-18087
58. Werner E.D., Lee J., Hansen L., Yuan M., and Shoelson S.E. Insulin resistance due to phosphorylation of insulin receptor substrate-1 at serine 302. J. Biol. Chem. 279 (2004) 35298-35305
59. White M.F. IRS proteins and the common path to diabetes. Am. J. Physiol: Endocrinol. Metab. 283 (2002) E413-E422
60. Zick Y. Insulin resistance: a phosphorylation-based uncoupling of insulin signaling. Trends Cell Biol. 11 (2001) 437-441
61. Zick Y. Uncoupling insulin signalling by serine/threonine phosphorylation: a molecular basis for insulin resistance. Biochem. Soc. Trans. 32 (2004) 812-816
62. Zick Y. Ser/Thr phosphorylation of IRS proteins: a molecular basis for insulin resistance. Sci. STKE. (2005) (pe4)